• Founded: 2013
  • Location: Framingham, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin3 (fast track)
  • Therapy area: Alzheimer's
  • Drug types: NEU, CVV, GEN, OPH, GER, MUS
  • Lead product: ALZ-801
  • Product link:
  • Funding: $50M D Apr 2022; $47M NIH grant Aug 2020; $10M A Apr 2015

job board

Short description:

Small Molecules targeting Alzheimer's

Drug notes:

Also 2 additional trials Clin2 Alzheimer's, Clin1 cerebral amyloid angiopathy, Down syndrome; ALZ-1903 Clin0 dry AMD, Clin0 inclusion body myositis, RD/Clin0 amyloid-related disorders

Long description:

Alzheon is developing medicines for patients with Alzheimer’s disease and other neurological disorders. The success rate with drugs to treat Alzheimer’s have a poor track record. Alzheon has been working to fix this by developing an oral drug that targets a key pathology in Alzheimer’s disease, amyloid-beta. The drug, ALZ-801, is currently the only anti-amyloid disease-modifying treatment in Phase 3 testing for Alzheimer’s disease. ALZ-801 works by targeting soluble amyloid oligomers that are suggested to trigger neuronal damage and cell death leading to Alzheimer’s disease. Using their precision medicine approach, Alzheon is initially focusing on the highest risk patients with two copies of the APOE4 gene, who are predicted to benefit most from ALZ-801.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy